Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2023 08:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
October 02, 2023 17:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.
September 21, 2023 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
August 31, 2023 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
August 09, 2023 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401...
August 02, 2023 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
May 10, 2023 16:19 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson...
May 03, 2023 08:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
May 02, 2023 07:50 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

TN-201 Being Developed for the Potential Treatment of MYBPC3-associated HCM Dosing in Phase 1 Clinical Trial Expected to Commence in Q3 2023 SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE...
April 21, 2023 16:05 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...